ArticleThrombosis research2026
Bleeding-related quality of life in older adults: Psychometric evaluation of the HEmorrhage Life Impact indeX (HELIX).
Article in Thrombosis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOlder adults treated with anticoagulants for atrial fibrillation (AF) or venous thromboembolism (VTE) face heightened bleeding risk, which can affect physical, emotional and social wellbeing and function. Existing instruments assess treatment satisfaction or generic quality of life but do not capture the specific impact of bleeding in this population. The goal of this study was to psychometrically validate HELIX (HEmorrhage Life Impact indeX), a novel patient-reported outcome (PRO) measure of bleeding-related quality of life in older adults on anticoagulation.
methodsWe enrolled adults aged ≥65 years with AF or VTE on oral anticoagulants. Psychometric testing of the previously derived, 19-item HELIX PRO included exploratory factor analysis, internal consistency (Cronbach's α), floor and ceiling effects, construct validity (correlations with PROMIS short forms), test-retest reliability (intraclass correlation coefficients), and responsiveness.
resultsNinety-five participants (mean age 75, 45% women, 87% White; 66% AF, 33% VTE) participated. Factor analysis identified two subscales: bleeding symptoms (6 items) and quality of life (13 items). Internal consistency was high overall (α = 0.91), excellent for quality of life (α = 0.95), and acceptable for bleeding symptoms (α = 0.61). HELIX scores showed no floor or ceiling effects and demonstrated expected convergent and divergent validity with PROMIS measures. Test-retest reliability was good-to-excellent for most items. Responsiveness analysis suggested HELIX was more sensitive to within-person change than PROMIS.
conclusionHELIX demonstrated strong initial psychometric performance as a bleeding-related quality of life instrument for older adults taking anticoagulants. It complements existing measures and warrants further validation in larger and more diverse populations to evaluate clinical utility and prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.